Clinical Trial

Disease: Metastatic Non-small Cell Lung Cancer, NSCLC, (NCT02793856)

Disease info:

Non-small cell lung cancer is the most common kind of lung cancer accounting for 80-85% of lung cancers, It is a disease in which malignant (cancer) cells form in the tissues of the lung. People who smoke or who breathe a lot of smoke are most likely to get NSCLC. Many of them are over 65.

Lung cancer is the most common cancer worldwide, accounting for 2.1 million new cases and 1.8 million deaths in 2018.
Official title:
A Phase I Clinical Trial of PD-1 Knockout Engineered T Cells Treating Patients With Advanced Non-small Cell Lung Cancer

Principal Investigator: You Lu, MD Chair of Department of Thoracic Cancer Sichuan University


Chengdu MedGenCell, Co., Ltd.


China, Sichuan


Study start:
Aug. 26, 2016
12 participants
Gene editing method:
Type of edit:
Gene disruption
Programmed cell death protein 1 (PD-1)
Delivery method:
Electroporation sgRNA plasmids - Ex-vivo
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Completed


This is a dose-escalation study of ex-vivo knocked-out, expanded, and selected PD-1 knockout-T cells from autologous origin. Patients are assigned to 1 of 3 treatment groups to determine the maximal tolerant dose. After the lower number of cycles are considered tolerant, an arm of the next higher number of cycles will be open to next patients. Biomarkers and immunological markers are collected and analyzed as well.
Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR-Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients.

Last updated: Apr. 10, 2022
Source: US National Institutes of Health (NIH)
Search CRISPR Medicine